Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 96OTHER_GOV 7INDUSTRY 7UNKNOWN 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Capecitabine 15Paclitaxel 13S 1 (combination) 9apatinib 8Oxaliplatin 8Carboplatin 8Cisplatin 7pyrotinib 6Epirubicin 6Docetaxel 6sintilimab 5camrelizumab 5anlotinib 5Radiotherapy 5Drug Therapy 5130-nm albumin-bound paclitaxel 5nimotuzumab 4nedaplatin 4Vinorelbine 4Temozolomide 4Irinotecan 4Fulvestrant 4Etoposide 4Bevacizumab 4toripalimab 3titanium silicide 3exemestane 3Trastuzumab 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × UNKNOWN × tislelizumab × Clear all
NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

ChineseAMS

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

ChineseAMS

Phase 2 Unknown
25 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡